Independent Coverage of the 2007 San Antonio Breast Cancer Symposium - CME

Bone Loss and Bone Metastases in Breast Cancer: A Report from the 2007 San Antonio Breast Cancer Symposium (SABCS) - CME

Denosumab Produces Promising Results Against Giant Cell Tumor of the Bone (6/10/2009)
Researchers involved in an international Phase II clinical trial have reported that 86% of patients with giant cell tumor of the bone responded to treatment with denosumab. These results were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on June 1.

Immunostimulant MTP Improves Survival in Pediatric Osteosarcoma (3/5/2008)
Researchers affiliated with the Children’s Oncology Group have shown that the addition of muramyl tripeptide (MTP) to chemotherapy improves survival in patients with osteosarcoma. The details of this study appeared in the February 1, 2008 issue of the Journal of Clinical Oncology.

Not Approvable Letter for Mifamurtide (9/19/2007)
IDM Pharma, Inc. has received a not approvable letter from the United States Food and Drug Administration (FDA) for their investigational drug mifamurtide (L-MTP-PE) – formerly Junovan – for the treatment of osteosarcoma.  

Neoadjuvant Chemotherapy Effective for Older Patients with Osteosarcoma (8/6/2007)
Researchers from Italy have reported that neoadjuvant chemotherapy improves prognosis and reduces amputations in patients over 40 years of age with localized osteosarcoma of the extremity. The details of this study appeared in the June, 2007 issue of Acta Orthopedica.

Radium-223 Effective for Hormone Refractory Prostate Cancer and Bone Metastases (7/9/2007)
Researchers from Sweden and Norway have reported that bone-targeted Radium-223 was associated with significant palliation in patients with hormone refractory prostate cancer (HRPC). The details of this randomized trial appeared in the July, 2007 issue of Lancet Oncology.